Publikationen in Zusammenarbeit mit Forschern von University of Sydney (4)

2020

  1. Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study

    British Journal of Haematology, Vol. 189, Núm. 1, pp. 84-96

2019

  1. Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma ¨

    Journal of Clinical Oncology

2018

  1. Ibrutinib as treatment for patients with relapsed/refractory follicular lymphoma: Results from the open-label, multicenter, phase II DAWN study

    Journal of Clinical Oncology, Vol. 36, Núm. 23, pp. 2405-2412

2017

  1. Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

    Journal of Clinical Oncology, Vol. 35, Núm. 22, pp. 2473-2481